These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

907 related items for PubMed ID: 28753799

  • 1. A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study.
    Davis N, Shtabsky A, Lew S, Rona R, Leibovitch I, Nativ O, Cohen M, Mor Y, Lindner U, Glickman Y, Matzkin H, Tsivian A, Gofrit O, Yossepovitch O.
    Eur Urol Focus; 2018 Apr; 4(3):388-394. PubMed ID: 28753799
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. What is the role of CellDetect® in detecting and monitoring bladder cancer?
    Yüksel Ö, Tosun Ç, Gümrükçü G, Tokuç E, Yücebaş ÖE.
    Urologia; 2023 May; 90(2):261-265. PubMed ID: 36660912
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of semaphorin 3A in patients with urothelial cancer.
    Vadasz Z, Rubinstein J, Bejar J, Sheffer H, Halachmi S.
    Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
    [Abstract] [Full Text] [Related]

  • 5. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

  • 6. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT, Casasola Chamorro J, Rodríguez Faba O, Martín Benito JL, Regadera Sejas FJ.
    Arch Esp Urol; 2002 Mar; 55(1):41-9. PubMed ID: 11957750
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Human complement factor H related protein test for monitoring bladder cancer.
    Raitanen MP, Marttila T, Nurmi M, Ala-Opas M, Nieminen P, Aine R, Tammela TL, Finnbladder Group.
    J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
    [Abstract] [Full Text] [Related]

  • 11. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
    Raitanen MP, Leppilahti M, Tuhkanen K, Forssel T, Nylund P, Tammela T, FinnBladder Group.
    Ann Chir Gynaecol; 2001 Feb; 90(4):261-5. PubMed ID: 11820414
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
    Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M.
    J Urol; 1998 Jun; 159(6):1876-80. PubMed ID: 9598479
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract.
    Konety BR, Metro MJ, Melham MF, Salup RR.
    Urol Int; 1999 Jun; 62(1):26-30. PubMed ID: 10436427
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
    Leyh H, Marberger M, Conort P, Sternberg C, Pansadoro V, Pagano F, Bassi P, Boccon-Gibod L, Ravery V, Treiber U, Ishak L.
    Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
    [Abstract] [Full Text] [Related]

  • 16. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
    Raitanen MP, FinnBladder Group.
    World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG, Nazir SA, Mallett S, Turney BW, Onwu NN, Roberts IS, Crew JP, Cowan NC.
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [Abstract] [Full Text] [Related]

  • 18. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
    Raitanen MP, Aine R, Kylmälä T, Kallio J, Liukkonen T, Tammela T, Finnbladder Group.
    Ann Chir Gynaecol; 2001 Jul; 90(4):256-9. PubMed ID: 11820413
    [Abstract] [Full Text] [Related]

  • 19. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer.
    Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, Zadra J, Burzon D, Osher G, Bridge JA, Anderson S, Johansson SL, Lieber M, Soloway M, Flom K.
    J Urol; 2002 Nov; 168(5):1950-4. PubMed ID: 12394683
    [Abstract] [Full Text] [Related]

  • 20. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder.
    Mian C, Lodde M, Haitel A, Egarter Vigl E, Marberger M, Pycha A.
    Urology; 2000 Aug 01; 56(2):228-31. PubMed ID: 10925083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.